Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916.
[2]
Young WF Jr. Primary Aldosteronism: A Common but Frequently Unrecognized Condition. Curr Atheroscler Rep. 2006;8(5):377-385.
[3]
Mulatero P, Monticone S, Deinum J, et al. Genetics, Prevalence, Screening and Confirmed Diagnosis. Nat Rev Endocrinol. 2022;18(11):655-664.
[4]
Vaidya A, Mulatero P, Kacirova N, et al. Subtype-Specific Approaches for Primary Aldosteronism. Endocr Rev. 2023;44(2):233-252.
[5]
American Academy of Family Physicians (AAFP). Primary Hyperaldosteronism: Diagnosis and Treatment Guidelines. Am Fam Physician. 2021;103(8):457-466.
[6]
Hannemann A, Wallaschofski H. Prevalence of Primary Aldosteronism in Today's World. Best Pract Res Clin Endocrinol Metab. 2022;36(3):101515.
[7]
Rossi GP, Seccia TM, Maniero C, et al. Drug-Induced Malignancy in Primary Aldosteronism. Hypertension. 2021;77(2):498-508.
[8]
Stowasser M, Wolley M, Wu A, et al. Pathogenesis of Familial Hyperaldosteronism. Nat Rev Endocrinol. 2019;15(10):603-616.
[9]
Baudrand R, Vaidya A. The Metabolic and Cardiovascular Effects of Aldosterone Excess. Endocrinol Metab Clin North Am. 2021;50(2):215-231.
[10]
Reincke M, Bancos I, Mulatero P, et al. Diagnosis and Classification of Primary Aldosteronism. Lancet Diabetes Endocrinol. 2021;9(12):876-892.